Enrico Margiotta

Mr. Enrico Margiotta

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2020 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
EMEnrico Margiotta
Enrico Margiotta
SLStephanie C. C. van der Lubbe
Stephanie C. C. van der Lubbe
LSLucas de Azevedo Santos
Lucas de Azevedo Santos
GPGabor Paragi
Gabor Paragi
Stefano MoroStefano Moro
Stefano Moro
CGCélia Fonseca Guerra
Célia Fonseca Guerra
Halogen bonds are highly important in medicinal chemistry as halogenation of drugs, generally, improves both selectivity and efficacy towards protein active sites. However, accurate modeling of halogen bond interactions remains a challenge, since a thorough theoretical investigation of the bonding mechanism, focusing on the realistic complexity of drug-receptor systems, is lacking. Our systematic quantum chemical study on ligand/peptide-like systems reveals that halogen bonding is driven by the same bonding interactions as hydrogen bonding. Besides the electrostatic and the dispersion interactions, our bonding analyses, based on quantitative Kohn–Sham molecular orbital theory together with the energy decomposition analysis, reveal that donor–acceptor interactions and steric repulsion between occupied orbitals of the halogenated ligand and the protein need to be considered more carefully within the drug design process.

11 August 2021 in ACS Infectious Diseases
Verified
Journal Article
Closed access
NDNapoleon D’cUnha
Napoleon D’cUnha
MMMohammad Moniruzzaman
Mohammad Moniruzzaman
KHKeith Haynes
Keith Haynes
GMGiuliano Malloci
Giuliano Malloci
CCConnor J. Cooper
Connor J. Cooper
JWJohn K. Walker
John K. Walker

1 September 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Stephanie FedericoStephanie Federico
Stephanie Federico
EMEnrico Margiotta
Enrico Margiotta
Veronica SalmasoVeronica Salmaso
Veronica Salmaso
GPGiorgia Pastorin
Giorgia Pastorin
SKSonja Kachler
Sonja Kachler
GSGiampiero Spalluto
Giampiero Spalluto

1 January 2020 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Stephanie FedericoStephanie Federico
Stephanie Federico
EMEnrico Margiotta
Enrico Margiotta
Stefano MoroStefano Moro
Stefano Moro
EKEszter Kozma
Eszter Kozma
ZGZhan-Guo Gao
Zhan-Guo Gao
GSGiampiero Spalluto
Giampiero Spalluto

18 February 2019 in MedChemComm
Verified
Journal Article
Closed access
PDF file
Stephanie FedericoStephanie Federico
Stephanie Federico
EMEnrico Margiotta
Enrico Margiotta
SPSilvia Paoletta
Silvia Paoletta
SKSonja Kachler
Sonja Kachler
KKKarl-Norbert Klotz
Karl-Norbert Klotz
GSGiampiero Spalluto
Giampiero Spalluto
A series of adenosine receptor antagonists bearing a reactive linker was developed. Functionalization of these derivatives is useful to easily obtain multi-target ligands, receptor probes, drug delivery systems, and diagnostic or theranostic systems. The pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine scaffold was chosen as a pharmacophore for the adenosine receptors. It was substituted at the 5 position with reactive linkers of different lengths. Then, these compounds were used to synthesise probes for the adenosine receptors by functionalization with a fluorescent moiety. Both series of compounds were evaluated for their binding at the four adenosine receptor subtypes. Different affinity and selectivity profiles were observed towards hA1, hA2A and hA3 adenosine receptors. In particular, fluorescent compounds behave as dual hA2A/hA3 ligands. Computational studies suggested different binding modes for developed compounds at the three receptors. Both molecular docking and supervised molecular dynamics (SuMD) simulations confirmed that the preferred binding mode at the single receptor was driven by the substitution present at the 5 position. Obtained results rationalized the compounds' binding profile at the adenosine receptors and pave the way for the development of more potent conjugable and conjugated ligands targeting these membrane receptors.